CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 98 enrolled
Drug / intervention
Escitalopram 20mg for 2 weeks +3 moredrug
Likely dose
Escitalopram 20mg for 2 weeksfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02161458
NCT02161458Phase 4Completed
CompareCT.gov

Escitalopram Effects on CSF Amyloid Beta Total Concentrations

University of Pennsylvania·interventional·Posted Jun 11, 2014·Updated Apr 9, 2020

In Brief

A Phase 4 clinical trial evaluating Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, and 2 other interventions for Amyloid Beta Protein. Completed, enrolled 98 participants across 2 sites.

Detailed Summary

Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures can be developed. The investigators have preliminary evidence that selective serotonin reuptake inhibitor (SSRI) antidepressants lower the amount of amyloid plaques in the human brain. The interventions now propose to study the effects of an SSRI (escitalopram) on levels of amyloid beta peptide (the major constituent of the plaques) in the cerebrospinal fluid (CSF) of cognitively normal older adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyloid Beta Protein
CountriesUnited States
CollaboratorsWashington University School of Medicine

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 11, 2014
Enrollment StartJun 1, 2014
Primary CompletionAug 1, 2017
Study CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.1 years ago

Interventions

Escitalopram 20mg for 2 weeksdrug

30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.

Escitalopram 20mg for 8 weeksdrug

30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.

Escitalopram 30mg for 8 weeksdrug

30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.

Placebodrug

Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.